Lindbrook Capital LLC Increases Position in Royalty Pharma plc (NASDAQ:RPRX)

Lindbrook Capital LLC raised its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 485.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,411 shares of the biopharmaceutical company’s stock after acquiring an additional 1,999 shares during the quarter. Lindbrook Capital LLC’s holdings in Royalty Pharma were worth $68,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in RPRX. Allworth Financial LP increased its holdings in Royalty Pharma by 89.8% during the 3rd quarter. Allworth Financial LP now owns 953 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 451 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Royalty Pharma by 112.0% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 1,005 shares of the biopharmaceutical company’s stock valued at $27,000 after acquiring an additional 531 shares in the last quarter. Rakuten Securities Inc. purchased a new position in Royalty Pharma during the 4th quarter valued at about $110,000. CWM LLC increased its holdings in Royalty Pharma by 75.9% during the 3rd quarter. CWM LLC now owns 4,782 shares of the biopharmaceutical company’s stock valued at $130,000 after acquiring an additional 2,064 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in Royalty Pharma by 10.8% during the 3rd quarter. PNC Financial Services Group Inc. now owns 5,509 shares of the biopharmaceutical company’s stock valued at $150,000 after acquiring an additional 536 shares in the last quarter. 54.35% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. JPMorgan Chase & Co. dropped their target price on shares of Royalty Pharma from $45.00 to $42.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. The Goldman Sachs Group decreased their price target on shares of Royalty Pharma from $56.00 to $50.00 and set a “buy” rating on the stock in a research note on Tuesday, February 20th. Bank of America decreased their price target on shares of Royalty Pharma from $40.00 to $38.00 and set a “buy” rating on the stock in a research note on Friday, April 12th. Finally, StockNews.com raised shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Thursday, April 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $46.75.

Royalty Pharma Price Performance

Royalty Pharma stock opened at $27.98 on Thursday. Royalty Pharma plc has a 1 year low of $25.92 and a 1 year high of $35.95. The firm has a 50 day moving average price of $29.69 and a 200 day moving average price of $28.54. The company has a market cap of $16.72 billion, a price-to-earnings ratio of 14.80 and a beta of 0.45. The company has a debt-to-equity ratio of 0.61, a quick ratio of 7.90 and a current ratio of 7.90.

Royalty Pharma (NASDAQ:RPRX) last released its earnings results on Thursday, February 15th. The biopharmaceutical company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.03 by $0.12. Royalty Pharma had a net margin of 48.22% and a return on equity of 26.93%. The firm had revenue of $736.00 million during the quarter, compared to the consensus estimate of $702.90 million. Sell-side analysts predict that Royalty Pharma plc will post 3.95 earnings per share for the current year.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 17th will be issued a $0.21 dividend. The ex-dividend date is Thursday, May 16th. This represents a $0.84 dividend on an annualized basis and a yield of 3.00%. Royalty Pharma’s payout ratio is 44.44%.

Royalty Pharma Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.